DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Alnylam Reports Positive Topline Results From APOLLO-B Phase 3 Study of Patisiran in Patients With ATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo (p-value 0.0162). The study also met the first secondary endpoint of change from baseline in quality of life compared to placebo, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) (p-value 0.0397).
The study also included additional secondary composite outcome endpoints to be tested in a hierarchical manner. A non-significant result (p-value 0.0574) was found on the secondary composite endpoint of all-cause mortality, frequency of cardiovascular events, and change from baseline in 6-MWT over 12 months compared to placebo. As a result, formal statistical testing was not performed on the final two composite endpoints, which were not powered for statistical significance given the short duration of the study — all-cause mortality and frequency of all-cause hospitalizations and urgent heart failure visits in patients not on tafamidis at baseline (nominal p-value 0.9888), and in the overall population (nominal p-value 0.5609). Patisiran also demonstrated an encouraging safety and tolerability profile, with deaths numerically favoring the patisiran arm.
people & placesStephen Heitner, MDStephen Heitner is a Senior Medical Dire...
videos & visualsHealth Insurance Basics, Terms, Options – ASG Webinar: Section 1/4https://www.youtube.com/watch?v=Pd6DVKeM...
news & meetingsMatt Millen, in Remission but Facing More Treatment, Plans TV Return This FallMatt Millen plans to return to the broad...
videos & visualsTreatment Update: Medications for Cardiac Amyloidosishttps://www.youtube.com/watch?v=zQAHpceU...
people & placesJeremy T. Larsen, MDJeremy T. Larsen is a Hematologist-Oncol...
educationAmyloidosis: A Unifying Diagnosis for Nephrotic Syndrome and Congestive Cardiac FailureDiagnosing patients simply with heart fa...
people & placesJing Fu, PhDDr. Jing Fu graduated with a Ph.D. in Bi...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.